901 Gateway Boulevard
South San Francisco
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the Closed Triple), currently in development for the treatment of COPD and asthma.
137 articles with Theravance Biopharma
Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) have been selected for an oral presentation at the 32nd European Neurology Congress.
Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
Induction and maintenance portions of study to evaluate gut-selective pan-JAK inhibitor in patients with moderately to severely active ulcerative colitis
8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019, at 9:00 a.m. ET. The conference will take place February 27 – March 1 at the Lotte New York Palace Hotel.
In the news release, Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26, issued 19-Feb-2019 by Theravance Biopharma, Inc.
January was a rough month for many pharma employees in California, as several companies pulled the trigger on layoffs, or announced coming layoffs that will affect hundreds of employees.
Despite the significant amount of finances invested in the Bay Area biotech environment, December and January saw a significant number of job cuts.
Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine (TD-9855) in patients with symptomatic neurogenic orthostatic hypotension (nOH).
uBiome has announced a 10% reduction in staff, amounting to 55 jobs, while Theravance recently announced layoffs of 50 workers. Both companies have a significant presence in San Francisco.
Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes
The notes are secured by a portion of the future payments the Company expects to receive related to royalties due on net sales of Trelegy Ellipta.
Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor
DUBLIN, /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first subject in a Phase 1 clinical trial of TD-8236, a novel, inhaled, lung-selective pan-Janus kinase (JAK) inhibitor which has demonstrated potency in preclinical assessments.
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease.
Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline or one of its affiliates pursuant to its agreements with Innoviva
The Food and Drug Administration is taking care of a few approvals and committee meetings ahead of the Thanksgiving holiday week. They include drugs for COPD, a pain drug, and a sublingual film formulation of a well-known drug for erectile dysfunction. Here’s a look.
[06-November-2018] DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV ® (telavancin), to Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Unde
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2018
Theravance Biopharma Reports Data from TD-1473 Phase 1b Four-Week Study in Oral Late-Breaker Presentation at UEG Week 2018
Presented Data Demonstrated Signals of Clinical and Biomarker Activity
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
Additional Analyses of Phase 3 Program Data Highlight Efficacy Advantages for 175 mcg/day of YUPELRI in Key Patient Subgroups, Demonstrate Acceptable Cardiovascular Safety Profile
Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Presentation to Highlight Positive Data Demonstrating Localized Target Engagement and Minimal Systemic Exposure following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD
Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe
Trelegy Ellipta is the triple combination therapy of FF/UMEC/VI in a single ELLIPTA® inhaler.